NICE approves CDF funding for Sanofi’s Libtayo
Around 560 patients per year with cutaneous squamous cell carcinoma are thought to be eligible for treatment with the drug in England
Read More
Tag: CSCC
US OKs Sanofi, Regeneron’s new skin cancer immunotherapy
Sanofi and Regeneron’s imunotherapy Libtayo has been cleared in the US to treat patients with certain forms of cutaneous squamous cell carcinoma (CSCC).
Read More
US priority review for Sanofi, Regeneron’s cemiplimab
US regulators are undertaking a priority review of Sanofi and Regeneron’s cemiplimab for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC), or those with locally advanced CSCC who are not candidates for surgery.
Read More
EU reviews for Sanofi’s Dupixent, cemiplimab
European regulators have agreed to review Sanofi and Regeneron’s Dupixent for asthma and cemiplimab for advanced cutaneous squamous cell carcinoma.
Read More
Sanofi, Regeneron ready to file cemiplimab
Sanofi and Regeneron are gearing up to file their experimental PD-1 inhibitor cemiplimab on both sides of the Atlantic following the drug’s success in clinical trials.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
